Sign in

Ralph Martini

Research Analyst at Private Investor

No publicly available information could be located regarding Ralph Martini serving as an analyst at Private Investor, including details on job title, company coverage, performance metrics, career timeline, or professional credentials. Searches returned no evidence of a LinkedIn profile or any industry recognition for an individual by this name and role. Consequently, a comprehensive professional profile cannot be provided at this time.

Ralph Martini's questions to Can-Fite BioPharma (CANF) leadership

Question · Q3 2020

Ralph Martini, a private investor, asked about the total cost of the terminated Rheumatoid Arthritis study, U.S. patent plans for Namodenoson, the 'fee for service' model for the cannabis assay, and the status of partnership discussions.

Answer

CFO Motti Farbstein reported the RA study cost was between $5 million and $6 million. CEO Pnina Fishman confirmed plans to pursue a U.S. patent for Namodenoson, explained the cannabis assay service identifies clinically active compounds via the A3AR target, and indicated that positive news on partnerships would be forthcoming in a future press release.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts